Hemophilia Inhibitor Genetics Study (HIGS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00166387|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment|
|Hemophilia A With Inhibitor||Procedure: Blood draw|
|Study Type :||Observational|
|Actual Enrollment :||1137 participants|
|Official Title:||Hemophilia Inhibitor Genetics Study (HIGS)|
|Study Start Date :||April 2003|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Phase I, II, III
Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
Procedure: Blood draw
A single blood draw.
Other Name: N/A to this study.
- development of inhibitory antibodies to factor VIII [ Time Frame: upon development of inhibitor or following at least 100 exposure days to factor VIII ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00166387
|Malmo University Hospital|
|Malmo, Sweden, SE-205 02|
|Principal Investigator:||Erik Berntorp, MD, PhD||Skane University Hospital|